ArticleEmerging infectious diseases2004
Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002.
Article in Emerging infectious diseases, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 166 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
166 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gloves, gowns and masks for reducing the transmission of meticillin-resistant Staphylococcus aureus (MRSA) in the hospital setting.The Cochrane database of systematic reviews · 2015Pooled it
- Population pharmacokinetics of teicoplanin in children.Antimicrobial agents and chemotherapy · 2014Trial
- Intervention to reduce transmission of resistant bacteria in intensive care.The New England journal of medicine · 2011Trial
- Phenotypic and Genotypic Analyses of Antimicrobial Resistance Patterns ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
- Methicillin-resistantCurrent pharmaceutical biotechnology · 2025Review
- Molecular Characteristics of Community-Acquired Methicillin-ResistantIndian journal of microbiology · 2024Article
- Molecular Evolution and Pathogenicity of Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Antimicrobial resistance: use of phage therapy in the management of resistant infections.Molecular biology reports · 2024Review
- Genetic Characterization of Antibiotic-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Increased Risk for Infections and Allergic Disease in Hereditary Hemorrhagic Telangiectasia.Journal of clinical medicine · 2024Article
- Zoonotic linkage and environmental contamination of Methicillin-resistantOne health (Amsterdam, Netherlands) · 2024Article
- Prevalence and Molecular Characterization of Methicillin-ResistantJournal of microbiology and biotechnology · 2022Article
- Poly(vinyl alcohol)/Plant Extracts Films: Preparation, Surface Characterization and Antibacterial Studies against Gram Positive and Gram Negative Bacteria.Materials (Basel, Switzerland) · 2022Article
- Article
- Exudative Epidermitis in Combination with Staphylococcal Pyoderma in Suckling Piglets.Antibiotics (Basel, Switzerland) · 2021Article
- High frequency of enterotoxin encoding genes of Staphylococcus aureus isolated from food and clinical samples.Journal of health, population, and nutrition · 2021Article
- Article
- Prevalence pattern of MRSA from a rural medical college of North India: A cause of concern.Journal of family medicine and primary care · 2021Article
- Epidemiology of Methicillin-Resistant Staphylococcus Aureus in Arab Countries of the Middle East and North African (MENA) Region.Mediterranean journal of hematology and infectious diseases · 2021Article
- Efficacy of Phage- and Bacteriocin-Based Therapies in Combatting Nosocomial MRSA Infections.Frontiers in molecular biosciences · 2021Review
106 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We explored the variation in proportions of methicillin-resistant Staphylococcus aureus (MRSA) between and within countries participating in the European Antimicrobial Resistance Surveillance System and temporal trends in its occurrence. This system collects routine antimicrobial susceptibility tests for S. aureus. We examined data collected from January 1999 through December 2002 (50,759 isolates from 495 hospitals in 26 countries). MRSA prevalence varied almost 100-fold, from <1% in northern Europe to >40% in southern and western Europe. MRSA proportions significantly increased in Belgium, Germany, Ireland, the Netherlands, and the United Kingdom, and decreased in Slovenia. Within countries, MRSA proportions varied between hospitals with highest variance in countries with a prevalence of 5% to 20%. The observed trends should stimulate initiatives to control MRSA at national, regional, and hospital levels. The large differences between hospitals indicate that efforts may be most effective at regional and hospital levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.